The two companies will adopt artificial intelligence and molecular modeling technology to develop drugs with fewer side effects. Molecular modeling encompasses all the theoretical and computational methods used to imitate the behavior of molecules. The method is used in the pharmaceutical sector to study various molecular systems including chemical molecules and material combinations.
inCerebro's AI-based drug development platform called "MIND" searches for new drug substances using quantum mechanical and molecular mechanical docking and water pharmacophore methods. It can also infer the structure of new drugs.
Quantum mechanical and molecular mechanical docking technology calculates molecular docking through quantum mechanics and analyzes factors. Docking modeling allows to efficiently develop drugs with fewer side effects by predicting how drugs combine with proteins in the body when administered.
Water pharmacophore analyzes protein structures and interactions with water molecules. It infers the form and structure of compounds that can be combined and provides information for AI.
SK Chemicals is in charge of verification, licensing, and production, while inCerebro is responsible for leading new drugs and deriving candidate materials for specific diseases based on its AI platform quantum mechanics-based molecular modeling technology.
"Through inCerebro's differentiated technology, we will be able to find new drug candidates more accurately and quickly," SK Chemical's research center head Kim Jeong-hoon said in a statement on April 11. In addition to developing new drugs, the two companies would seek opportunities for the commercialization of materials in the search stage.
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.